Bluebird Bio, Inc. (BLUE)

NASDAQ: BLUE · IEX Real-Time Price · USD
6.79
+0.66 (10.77%)
At close: Oct 4, 2022 4:00 PM
6.69
-0.10 (-1.47%)
After-hours: Oct 4, 2022 7:59 PM EDT
10.77%
Market Cap 523.66M
Revenue (ttm) -13.14M
Net Income (ttm) -594.16M
Shares Out 77.12M
EPS (ttm) -10.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,469,487
Open 6.24
Previous Close 6.13
Day's Range 6.24 - 6.79
52-Week Range 2.87 - 17.85
Beta 1.16
Analysts Hold
Price Target 7.93 (+16.8%)
Earnings Date Nov 3, 2022

About BLUE

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo... [Read more...]

Industry Biotechnology
IPO Date Jun 19, 2013
Employees 518
Stock Exchange NASDAQ
Ticker Symbol BLUE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for BLUE stock is "Hold." The 12-month stock price forecast is 7.93, which is an increase of 16.79% from the latest price.

Price Target
$7.93
(16.79% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Should You Buy the Dip With Bluebird Bio?

The near term looks good, but the long term might not.

14 hours ago - The Motley Fool

bluebird's (BLUE) Gene Therapy Approvals to Drive the Top Line

bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, are expected to drive the top line.

1 day ago - Zacks Investment Research

World's Most Expensive Drugs Can't Cure What Ails This Biotech

Bluebird Bio has received a lot of attention for pricing two FDA-approved gene therapies at around $3 million annually, but its financial future remains uncertain.

1 day ago - WSJ

Why Bluebird Bio Stock Is Taking Flight Today

The biotech stands out as a possible buyout target.

4 days ago - The Motley Fool

Is This Growth Stock Undervalued?

This biotech has made tremendous progress recently.

1 week ago - The Motley Fool

Do Back-to-Back Approvals Make This Biotech Stock a Buy Now?

This drugmaker has earned two new drug approvals in as many months, but its success isn't reflected in its market valuation yet.

1 week ago - The Motley Fool

Bluebird (BLUE) Surges 15.7%: Is This an Indication of Further Gains?

Bluebird (BLUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

1 week ago - Zacks Investment Research

2 Small Caps for Growth-Focused Investors

Investors seeking opportunities among growth stocks could be interested in the following small caps, as they represent companies whose trailing 12-month net income per share has improved significantly o...

Other symbols: PL
1 week ago - GuruFocus

Why Shares of Bluebird Bio Jumped 15.7% on Tuesday

Investors, prodded by analysts, warmed up to the company after another FDA-approved therapy.

2 weeks ago - The Motley Fool

bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD

bluebird's (BLUE) Syskona (eli-cel) gets FDA approval for early, active cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age.

2 weeks ago - Zacks Investment Research

Bluebird Bio stock falls after FDA approves gene therapy

Yahoo Finance's Brad Smith and Julie Hyman discusses the reversal in Bluebird Bio shares after the FDA approved its second gene therapy.

2 weeks ago - Yahoo Finance

Bluebird Bio (BLUE) Stock Is in Focus Following FDA Approval

Shares of Bluebird Bio (NASDAQ: BLUE ) were trending higher today in premarket trading on news that the U.S. Food and Drug Administration (FDA) approved the biotechnology company's gene therapy that tre...

2 weeks ago - InvestorPlace

Bluebird Bio Stock Soars on FDA Approval of Gene Therapy for Rare Neurological Disease

The company anticipates the product to be available by the end of 2022.

2 weeks ago - Barrons

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystro...

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced the U.S. Food and Drug Administration (FDA) has granted Accelerated Approval of SKYSONA® (elivaldogene autotemcel), ...

2 weeks ago - Business Wire

2 Risky Stocks That Are Running Low on Cash

Is it worth taking a chance on these stocks?

Other symbols: BBBY
3 weeks ago - The Motley Fool

Jason Cole, Chief Strategy and Financial Officer, to Depart bluebird bio This Fall

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that Jason Cole, Chief Strategy and Financial Officer, plans to leave bluebird bio to pursue new career opportunitie...

3 weeks ago - Business Wire

These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge

Think twice before investing in these companies.

Other symbols: PLNHF
3 weeks ago - The Motley Fool

Avoid Buying the Dip With These 2 Stocks During the Nasdaq Bear Market

Both are facing significant challenges that might get worse before they get better.

Other symbols: TDOC
4 weeks ago - The Motley Fool

10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others

Biotech stocks are scorching right now. But the best of the best have strong gains.

Other symbols: AXSMALNYKRTX
1 month ago - Investors Business Daily

bluebird bio Announces September Investor Events

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: 2022 Wells Farg...

1 month ago - Business Wire

bluebird (BLUE) Up 101% in the Past Three Months: Here's Why

bluebird bio (BLUE) has surged in the past three months owing to its pipeline development. The company's lead candidate recently received FDA approval as a potential treatment for beta-thalassemia.

1 month ago - Zacks Investment Research

Should You Buy This Growth Stock Following a Major Approval?

This biotech really needed some good news.

1 month ago - The Motley Fool

Why Bluebird Bio's Stock Dived by Over 11% This Week

Analysts were lukewarm on the seemingly very positive news reported by the company midweek.

1 month ago - The Motley Fool

BLUE Stock Moves as FDA Approves Bluebird Bio's Gene Therapy

Source: rafapress / Shutterstock Bluebird Bio (NASDAQ: BLUE ) stock is on the move Thursday following U.S. Food and Drug Administration (FDA) approval for ZYNTEGLO. ZYNTEGLO is a gene therapy designed f...

1 month ago - InvestorPlace

bluebird's (BLUE) Gene Therapy Gets FDA Nod for Beta-Thalassemia

bluebird's (BLUE) Zynteglo gets FDA-approval for transfusion-dependent beta-thalassemia in adult and pediatric patients. The stock gains.

1 month ago - Zacks Investment Research